Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies
A comprehensive list of the clinical trials and their registration numbers is reported in Table S1 of the supplemental material.
Authors
- Arnon Dov Cohen (ORCID: https://orcid.org/0000-0002-8377-9982)
- Areti Eleftheriadi
- Nadezhda Eberhart (ORCID: https://orcid.org/0000-0002-7170-7148)
- Carlos Mauricio Castaño Díaz (ORCID: https://orcid.org/0000-0001-8189-7523)
- L. Puig (ORCID: https://orcid.org/0000-0001-6083-0952)
- Saakshi Khattri (ORCID: https://orcid.org/0000-0002-5295-8726)
- Marcus Ngantcha
- Alyssa Garrelts
- Alice Bendix Gottlieb (ORCID: https://orcid.org/0000-0002-2927-8618)
- Sergio Schwartzman (ORCID: https://orcid.org/0000-0001-9221-891X)
- Christian Jossart (ORCID: https://orcid.org/0000-0002-5342-7409)
- Nithi Tangsirisap (ORCID: https://orcid.org/0009-0000-3016-8371)
- Christopher Schuster (ORCID: https://orcid.org/0000-0001-5126-3853)
Institutions
- Hospital for Special Surgery (US)
- Eli Lilly (United States) (US)
- Hospital de Sant Pau (ES)
- Clalit Health Services (IL)
- Medical University of Vienna (AT)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1080/14740338.2024.2399092
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.48
Funders
- Eli Lilly and Company